David Hoang
Stock Analyst at Deutsche Bank
(1.85)
# 3,048
Out of 4,854 analysts
39
Total ratings
36.67%
Success rate
-8.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $21.96 | +59.38% | 5 | May 21, 2025 | |
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $31.69 | +64.12% | 2 | Mar 27, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $124 → $99 | $43.01 | +130.18% | 6 | Mar 19, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $31.63 | +111.82% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $44.59 | +148.93% | 1 | Feb 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $55 | $35.57 | +54.62% | 2 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.70 | +110.88% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $17.03 | +281.68% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $111.91 | +57.27% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $9.73 | +23.33% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $125.39 | +26.01% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.21 | +478.51% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $8 | $6.84 | +16.96% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.54 | +252.42% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.54 | +351.98% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $300.83 | -26.87% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $16.81 | +375.91% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.33 | +125.56% | 1 | Dec 7, 2022 |
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $21.96
Upside: +59.38%
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $31.69
Upside: +64.12%
Sarepta Therapeutics
Mar 19, 2025
Maintains: Hold
Price Target: $124 → $99
Current: $43.01
Upside: +130.18%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $31.63
Upside: +111.82%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $44.59
Upside: +148.93%
Harmony Biosciences Holdings
Feb 11, 2025
Initiates: Buy
Price Target: $55
Current: $35.57
Upside: +54.62%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.70
Upside: +110.88%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $17.03
Upside: +281.68%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $111.91
Upside: +57.27%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $9.73
Upside: +23.33%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $125.39
Upside: +26.01%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.21
Upside: +478.51%
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $6.84
Upside: +16.96%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $4.54
Upside: +252.42%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.54
Upside: +351.98%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $300.83
Upside: -26.87%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $16.81
Upside: +375.91%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.33
Upside: +125.56%